BIGBEAR
PHARMACEUTICAL
Mobocertinib achieves targeted antitumor effects by precisely inhibiting the mutant target to block tumor cell proliferation and survival.
AuthenticGuaranteeFast DeliveryPrivacy Takeda Pharmaceutical recently presented updated data from a Phase 1/2 clinical trial of its oral targeted anticancer drug mobocertinib (TAK-788) for ···【More】
Update: 20 Mar,2026Source: BigbearViews: 89
Takeda Pharmaceutical recently announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review its New Drug Applic···【More】
Update: 20 Mar,2026Source: BigbearViews: 88
Summary: EGFR Exon20ins+ non-small cell lung cancer (NSCLC) is an extremely rare cancer, primarily affecting young adults and non-smokers. Its prognos···【More】
Update: 20 Mar,2026Source: BigbearViews: 90
On September 15, 2021, Takeda Pharmaceutical Company of Japan announced accelerated approval from the FDA for Exkivity (mobocertinib) for the treatmen···【More】
Update: 20 Mar,2026Source: BigbearViews: 90
Recently, the UK's National Institute for Health and Care Excellence (NICE) released its final guidelines, recommending Exkivity (Mobocertinib) fo···【More】
Update: 20 Mar,2026Source: BigbearViews: 89
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
